CXCL8 and non-small cell lung carcinoma: In another retrospective analysis of 755 patients with advanced cancers (RCC (n = 392), squamous NSCLC (n = 108), or nonsquamous NSCLC (n = 255)) receiving αPD‐1 agents, baseline levels of serum IL‐8 > 23 pg/mL were uniformly associated with significantly shorter OS (Figure 2).38